Hellke P - Search Results

Year	Number of Results
1998	1
2005	1
2006	1
2007	2
2009	1
2011	1
2024	0

1

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators. Dormandy JA, et al. Lancet. 2005 Oct 8;366(9493):1279-89. doi: 10.1016/S0140-6736(05)67528-9. Lancet. 2005. PMID: 16214598 Free article. Clinical Trial.

2

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators. Erdmann E, et al. J Am Coll Cardiol. 2007 May 1;49(17):1772-80. doi: 10.1016/j.jacc.2006.12.048. Epub 2007 Apr 16. J Am Coll Cardiol. 2007. PMID: 17466227 Free article. Clinical Trial.

3

Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study.

Pfister R, Cairns R, Erdmann E, Schneider CA; PROactive investigators. Pfister R, et al. Diabet Med. 2011 Oct;28(10):1206-12. doi: 10.1111/j.1464-5491.2011.03281.x. Diabet Med. 2011. PMID: 21388447 Free article.

4

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA; PROactive Investigators. Erdmann E, et al. Diabetes Care. 2007 Nov;30(11):2773-8. doi: 10.2337/dc07-0717. Epub 2007 Jul 31. Diabetes Care. 2007. PMID: 17666462 Clinical Trial.

5

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team. Home PD, et al. Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6. Lancet. 2009. PMID: 19501900 Clinical Trial.

6

Time to relief of episodic symptoms of gastro-oesophageal reflux disease. A crossover comparison of single doses of the effervescent and standard formulations of ranitidine.

Elm M, Hellke P, Andrén K, Dahl G, Nyth AL. Elm M, et al. Among authors: hellke p. Scand J Gastroenterol. 1998 Sep;33(9):900-4. doi: 10.1080/003655298750026886. Scand J Gastroenterol. 1998. PMID: 9759942 Clinical Trial.

7

Influenza work on the regional level in Sweden: an integrated program for vaccination of risk groups, surveillance and pandemic planning which focuses on the role of the health care worker.

Stenqvist K, Hellvin MA, Hellke P, Höglund D, von Sydow H. Stenqvist K, et al. Among authors: hellke p. Vaccine. 2006 Nov 10;24(44-46):6712-6. doi: 10.1016/j.vaccine.2006.05.098. Epub 2006 Jun 14. Vaccine. 2006. PMID: 16860442

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

7 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year